Current Treatment Strategies for Heart Failure: Role of Device Therapy and LV Reconstruction

Praneeth Janaswamy, Tomos E. Walters, Babak Nazer, Randall J. Lee

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Medical care of heart failure (HF) begins with the determination of the cause of the heart failure and diagnosing potential reversible causes (i.e., coronary heart disease, hyperthyroidism, etc.). Medical therapy includes pharmacological and nonpharmacological strategies that limit and/or reverse the signs and symptoms of HF. Initial behavior modification includes dietary sodium and fluid restriction to avoid weight gain; and encouraging physical activity when appropriate. Optimization of medical therapy is the first line of treatment that includes the use of diuretics, vasodilators (i.e., ACE inhibitors or ARBs), beta blockers, and potentially inotropic agents and anticoagulation depending on the patient’s severity of heart failure and LV dysfunction. As heart failure advances despite optimized medical management, cardiac resynchronization therapy (CRT), and implantable cardioverter defibrillators (ICDs) are appropriate device therapies. The development of progressive end-stage HF, despite maximal medical therapy, necessitates the consideration of mechanical circulatory devices such as ventricular assist devices (VADs) either as a bridge to heart transplantation or as destination therapy. Despite the advances in the treatment of heart failure, there is still a large morbidity and mortality associated with HF, thus the need to develop newer strategies for the treatment of HF.

Original languageEnglish (US)
Article number57
JournalCurrent Treatment Options in Cardiovascular Medicine
Volume18
Issue number9
DOIs
StatePublished - Sep 1 2016
Externally publishedYes

Fingerprint

Heart Failure
Equipment and Supplies
Therapeutics
Treatment Failure
Dietary Sodium
Cardiac Resynchronization Therapy
Heart-Assist Devices
Implantable Defibrillators
Behavior Therapy
Hyperthyroidism
Heart Transplantation
Vasodilator Agents
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Anticoagulants
Signs and Symptoms
Weight Gain
Coronary Disease
Pharmacology
Exercise

Keywords

  • Cardiac resynchronization therapy
  • Heart failure
  • ICD
  • Tissue engineering

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Current Treatment Strategies for Heart Failure : Role of Device Therapy and LV Reconstruction. / Janaswamy, Praneeth; Walters, Tomos E.; Nazer, Babak; Lee, Randall J.

In: Current Treatment Options in Cardiovascular Medicine, Vol. 18, No. 9, 57, 01.09.2016.

Research output: Contribution to journalReview article

@article{166306aa4f0348afb6eefd28a1a28ff5,
title = "Current Treatment Strategies for Heart Failure: Role of Device Therapy and LV Reconstruction",
abstract = "Medical care of heart failure (HF) begins with the determination of the cause of the heart failure and diagnosing potential reversible causes (i.e., coronary heart disease, hyperthyroidism, etc.). Medical therapy includes pharmacological and nonpharmacological strategies that limit and/or reverse the signs and symptoms of HF. Initial behavior modification includes dietary sodium and fluid restriction to avoid weight gain; and encouraging physical activity when appropriate. Optimization of medical therapy is the first line of treatment that includes the use of diuretics, vasodilators (i.e., ACE inhibitors or ARBs), beta blockers, and potentially inotropic agents and anticoagulation depending on the patient’s severity of heart failure and LV dysfunction. As heart failure advances despite optimized medical management, cardiac resynchronization therapy (CRT), and implantable cardioverter defibrillators (ICDs) are appropriate device therapies. The development of progressive end-stage HF, despite maximal medical therapy, necessitates the consideration of mechanical circulatory devices such as ventricular assist devices (VADs) either as a bridge to heart transplantation or as destination therapy. Despite the advances in the treatment of heart failure, there is still a large morbidity and mortality associated with HF, thus the need to develop newer strategies for the treatment of HF.",
keywords = "Cardiac resynchronization therapy, Heart failure, ICD, Tissue engineering",
author = "Praneeth Janaswamy and Walters, {Tomos E.} and Babak Nazer and Lee, {Randall J.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1007/s11936-016-0479-1",
language = "English (US)",
volume = "18",
journal = "Current Treatment Options in Cardiovascular Medicine",
issn = "1092-8464",
publisher = "Current Science, Inc.",
number = "9",

}

TY - JOUR

T1 - Current Treatment Strategies for Heart Failure

T2 - Role of Device Therapy and LV Reconstruction

AU - Janaswamy, Praneeth

AU - Walters, Tomos E.

AU - Nazer, Babak

AU - Lee, Randall J.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Medical care of heart failure (HF) begins with the determination of the cause of the heart failure and diagnosing potential reversible causes (i.e., coronary heart disease, hyperthyroidism, etc.). Medical therapy includes pharmacological and nonpharmacological strategies that limit and/or reverse the signs and symptoms of HF. Initial behavior modification includes dietary sodium and fluid restriction to avoid weight gain; and encouraging physical activity when appropriate. Optimization of medical therapy is the first line of treatment that includes the use of diuretics, vasodilators (i.e., ACE inhibitors or ARBs), beta blockers, and potentially inotropic agents and anticoagulation depending on the patient’s severity of heart failure and LV dysfunction. As heart failure advances despite optimized medical management, cardiac resynchronization therapy (CRT), and implantable cardioverter defibrillators (ICDs) are appropriate device therapies. The development of progressive end-stage HF, despite maximal medical therapy, necessitates the consideration of mechanical circulatory devices such as ventricular assist devices (VADs) either as a bridge to heart transplantation or as destination therapy. Despite the advances in the treatment of heart failure, there is still a large morbidity and mortality associated with HF, thus the need to develop newer strategies for the treatment of HF.

AB - Medical care of heart failure (HF) begins with the determination of the cause of the heart failure and diagnosing potential reversible causes (i.e., coronary heart disease, hyperthyroidism, etc.). Medical therapy includes pharmacological and nonpharmacological strategies that limit and/or reverse the signs and symptoms of HF. Initial behavior modification includes dietary sodium and fluid restriction to avoid weight gain; and encouraging physical activity when appropriate. Optimization of medical therapy is the first line of treatment that includes the use of diuretics, vasodilators (i.e., ACE inhibitors or ARBs), beta blockers, and potentially inotropic agents and anticoagulation depending on the patient’s severity of heart failure and LV dysfunction. As heart failure advances despite optimized medical management, cardiac resynchronization therapy (CRT), and implantable cardioverter defibrillators (ICDs) are appropriate device therapies. The development of progressive end-stage HF, despite maximal medical therapy, necessitates the consideration of mechanical circulatory devices such as ventricular assist devices (VADs) either as a bridge to heart transplantation or as destination therapy. Despite the advances in the treatment of heart failure, there is still a large morbidity and mortality associated with HF, thus the need to develop newer strategies for the treatment of HF.

KW - Cardiac resynchronization therapy

KW - Heart failure

KW - ICD

KW - Tissue engineering

UR - http://www.scopus.com/inward/record.url?scp=84982862083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982862083&partnerID=8YFLogxK

U2 - 10.1007/s11936-016-0479-1

DO - 10.1007/s11936-016-0479-1

M3 - Review article

AN - SCOPUS:84982862083

VL - 18

JO - Current Treatment Options in Cardiovascular Medicine

JF - Current Treatment Options in Cardiovascular Medicine

SN - 1092-8464

IS - 9

M1 - 57

ER -